Cavidi

About

Cavidi AB is a Swedish biotechnology company based in Uppsala, founded in 1984. The company specializes in ultra-sensitive biomarker detection technologies, initially focusing on HIV monitoring and later expanding to innovative immunoassay signal amplification. Cavidi's flagship product, Exazym®, utilizes Binding Oligo Ladder Detection (BOLD) technology, offering significant signal amplification and lower detection limits for standard immunoassays. This product is compatible with most existing systems and is designed for research-use-only applications. Cavidi aims to commercialize Exazym® and BOLD through direct sales, licensing agreements, and partnerships for in-vitro diagnostic applications. The company targets precision health and biomarker discovery, particularly in high-disease-burden areas like HIV. With a dedicated team of around 28 employees, Cavidi continues to innovate and support researchers with customer service, troubleshooting, and collaboration on new immunoassay development.